World Market for Prescription Dermatological Drugs, 9th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
The worldwide market for prescription dermatological drugs encompasses a wide variety of products that treat disorders of the skin as well as the effects of aging. It’s a very dynamic time for the prescription dermatological drug industry. Consolidation, economic times, new technologies and genetic discoveries are among the trends that the industry is seeing.
Dermatological drugs are currently experiencing a busy and interesting period and, as a result, the range of therapeutic options available to physicians has expanded.This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the ninth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors that may help to shape the market for treatments in the future.
The driving forces for the dermatology drug market include growth and aging of the worldwide population, new products and technologies, and focus on lifestyle treatments that improve the effects of aging and damage to the skin. Within the pharmaceutical industry as a whole, financial depression, consolidation and economic downturns have influenced the market.
The worldwide market for prescription dermatology drugs includes products in the following categories:
- Prescription Acne and Rosacea Drugs
- Prescription Antiaging and Photodamage Drugs
- Prescription Dermatitis and Seborrhea Drugs
- Prescription Fungal Infection Drugs
- Prescription Hair Loss and Hair Removal Drugs
- Prescription Hyperpigmentation/Melasma Drugs
- Prescription Psoriasis Drugs
- Prescription Skin Cancer Drugs
- Other Prescription Skin Disorder Drugs
This report details the various categories of prescription dermatological drugs, describes the worldwide market for prescription dermatological drugs, and identifies major market factors that may help to shape the worldwide market for prescription dermatological drugs in the future.
The pharmaceutical industry is facing a tougher environment in general, due to harder regulations for gaining approvals for mainstream products, economic issues, and a dwindling pipeline of new products. Reliance on blockbuster drugs is all but over, causing a shift of focus for many drug research and development entities. By focusing on cosmetic medications, many manufacturers are realizing less scrutiny from the FDA and a growing need in the niche markets such as dermatology. This transition will play a role in the future development of the dermatological industry over the forecast period. The worldwide pharmaceutical sector has little choice but to continue expanding through mergers and acquisitions for some time to come. The sector is ripe for the picking, too, with the financial crisis having created an impressive buyer’s market for larger companies, as smaller firms struggle to extend financing. True globalization of pharmaceuticals has arrived. Most of the growth in the next few years will be outside the US, Europe and Japan. It’s a very dynamic time for the industry focusing on a worldwide market.
The information and analysis presented in this report are based on extensive interviews with senior management of top companies in the dermatology market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 30 industry executives and product managers to validate and obtain expert opinion on current and future trends in the dermatological market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.
All market data pertains to the worldwide market at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2015. Historical data are provided for each of the years 2013 to 2014, and forecast data are provided for each of the years 2015 through 2020. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2015 base year.
The following companies are profiled in this report:
Allergan Inamed Corporation
Barrier Therapeutics, Inc
PharmaDerm Pharmaceuticals, Inc
Collagenex (now Galderma) Pharmaceuticals
Johnson & Johnson (Janssen Pharmaceutica, Ortho Dermatological, Ortho-McNeil)
Medicis Pharmaceutical Corporation
Merck & Company, Inc.
Mylan Pharmaceuticals, Inc,
Novartis Pharmaceuticals Corporation
Roche Group (F. Hoffmann-La Roche Ltd.)
Schering (now Merck)-Plough Corporation
Sinclair Pharma Plc.
Stiefel Laboratories, Inc.
Valeant Pharmaceuticals, Inc.